Sonic Healthcare Ltd (ASX: SHL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Sonic Healthcare Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Sonic Healthcare Ltd (ASX: SHL)
Latest News
Dividend Investing
2 strong ASX dividend shares hiding in plain sight
Broker Notes
Broker names 3 more ‘champion’ ASX 200 shares to buy and hold
Blue Chip Shares
2 ASX 200 blue chip shares to buy in May: Analysts
Share Market News
2 defensive ASX dividend shares for long-term income
Healthcare Shares
3 reasons why the Sonic Healthcare (ASX:SHL) share price could be an opportunity
Best Shares
Top ASX shares to buy in April 2022
Healthcare Shares
Why these 3 ASX healthcare shares could get a boost from the federal budget
Dividend Investing
Are these 2 ASX dividend shares top buys for income in April?
Frequently Asked Questions
-
Sonic Healthcare traditionally makes two partially or fully franked dividend payments to shareholders every year, in March and September. Most recently, the company paid a fully franked interim dividend of 40 cents per share on 23 March 2022.
-
Yes, Sonic Healthcare offers a dividend reinvestment plan (DRP) as an alternative to receiving cash dividends on its ordinary shares.
Dividend Payment History Data provided by Morningstar.
Ex-Date | Amount | Franking | Type | Payable |
---|---|---|---|---|
08 Mar 2022 | $0.4000 | 100.00% | Interim | 23 Mar 2022 |
07 Sep 2021 | $0.5500 | 65.00% | Final | 22 Sep 2021 |
09 Mar 2021 | $0.3600 | 30.00% | Interim | 24 Mar 2021 |
07 Sep 2020 | $0.5100 | 30.00% | Final | 22 Sep 2020 |
10 Mar 2020 | $0.3400 | 30.00% | Interim | 25 Mar 2020 |
10 Sep 2019 | $0.5100 | 30.00% | Final | 25 Sep 2019 |
08 Mar 2019 | $0.3300 | 20.00% | Interim | 26 Mar 2019 |
12 Sep 2018 | $0.4900 | 30.00% | Final | 27 Sep 2018 |
06 Mar 2018 | $0.3200 | 20.00% | Interim | 10 Apr 2018 |
08 Sep 2017 | $0.4600 | 20.00% | Final | 11 Oct 2017 |
07 Mar 2017 | $0.3100 | 20.00% | Interim | 11 Apr 2017 |
08 Sep 2016 | $0.4400 | 30.00% | Final | 27 Sep 2016 |
03 Mar 2016 | $0.3000 | 30.00% | Interim | 06 Apr 2016 |
09 Sep 2015 | $0.4100 | 55.00% | 22 Oct 2015 | |
06 Mar 2015 | $0.2900 | 55.00% | 25 Mar 2015 | |
05 Sep 2014 | $0.4000 | 55.00% | Final | 23 Sep 2014 |
03 Sep 2012 | $0.3500 | 45.00% | Final | 09 Oct 2012 |
04 Mar 2011 | $0.2400 | 27.92% | Interim | 24 Mar 2011 |
08 Sep 2010 | $0.3500 | 35.00% | Final | 28 Sep 2010 |
03 Mar 2010 | $0.2400 | 35.00% | Interim | 25 Mar 2010 |
08 Sep 2009 | $0.3500 | 35.00% | Final | 28 Sep 2009 |
05 Mar 2009 | $0.2200 | 60.00% | Interim | 26 Mar 2009 |
SHL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Sonic Healthcare Ltd
Sonic Healthcare Limited (ASX: SHL) is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the United Kingdom, the second-largest in Belgium and New Zealand and the third-largest in the United States.
While pathology contributes roughly 85% of group revenue, Sonic Healthcare is a major provider of diagnostic imaging in Australia and also is this country's largest medical centre operator. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the US and 35% in Europe.
SHL Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
13 May 2022 | $36.05 | $0.87 | 2.47% | 887,826 | $35.53 | $36.10 | $35.33 |
12 May 2022 | $35.18 | $-0.06 | -0.17% | 905,216 | $35.14 | $35.35 | $34.90 |
11 May 2022 | $35.24 | $0.46 | 1.32% | 1,509,911 | $34.60 | $35.38 | $34.37 |
10 May 2022 | $34.78 | $-0.83 | -2.33% | 2,041,508 | $35.25 | $35.33 | $34.54 |
09 May 2022 | $35.61 | $-0.33 | -0.92% | 861,160 | $35.99 | $36.03 | $35.31 |
06 May 2022 | $35.94 | $-0.53 | -1.45% | 1,553,858 | $36.04 | $36.12 | $35.36 |
05 May 2022 | $36.47 | $0.06 | 0.16% | 784,217 | $36.40 | $36.68 | $36.14 |
04 May 2022 | $36.41 | $0.36 | 1.00% | 761,527 | $36.23 | $36.44 | $36.03 |
03 May 2022 | $36.05 | $0.03 | 0.08% | 837,890 | $36.03 | $36.40 | $35.97 |
02 May 2022 | $36.02 | $-0.71 | -1.93% | 789,335 | $36.38 | $36.44 | $35.96 |
29 Apr 2022 | $36.73 | $0.73 | 2.03% | 1,352,010 | $36.42 | $36.77 | $36.24 |
28 Apr 2022 | $36.00 | $-0.55 | -1.50% | 1,177,978 | $36.51 | $36.68 | $35.89 |
27 Apr 2022 | $36.55 | $-0.14 | -0.38% | 1,131,179 | $36.51 | $36.82 | $36.39 |
26 Apr 2022 | $36.69 | $0.28 | 0.77% | 1,315,020 | $36.46 | $36.87 | $36.41 |
22 Apr 2022 | $36.41 | $-0.74 | -1.99% | 1,572,949 | $36.59 | $36.86 | $36.38 |
21 Apr 2022 | $37.15 | $0.78 | 2.14% | 1,719,365 | $37.45 | $37.46 | $36.69 |
20 Apr 2022 | $36.37 | $0.87 | 2.45% | 1,403,587 | $36.20 | $36.73 | $36.06 |
19 Apr 2022 | $35.50 | $-0.02 | -0.06% | 851,881 | $35.35 | $35.75 | $35.20 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
02 Mar 2022 | Christopher Wilks | Transfer | 26 | $922,220 | As advised by the company. 26,934 shares were withdrawn from SHEST and legal title transferred to Mr Wilks |
02 Mar 2022 | Colin Goldschmidt | Transfer | 60 | $2,075,834 | As advised by the company. 60,626 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt. |
02 Mar 2022 | Colin Goldschmidt | Transfer | 60 | $2,075,834 | As advised by the company. 60,626 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt. |
02 Mar 2022 | Christopher Wilks | Transfer | 26 | $922,220 | As advised by the company. 26,934 shares were withdrawn from SHEST and legal title transferred to Mr Wilks |
01 Mar 2022 | Colin Goldschmidt | Exercise | 92 | $3,195,677 | Conversion of securities. 134,763 - Performance Rights |
01 Mar 2022 | Colin Goldschmidt | Buy | 92 | $3,195,677 | Conversion of securities. |
01 Mar 2022 | Christopher Wilks | Exercise | 43 | $1,503,672 | Conversion of securities. 54,195 - Performance Rights |
01 Mar 2022 | Christopher Wilks | Buy | 43 | $1,503,672 | Conversion of securities. |
18 Nov 2021 | Colin Goldschmidt | Issued | 39 | $1,566,507 | Issue of securities. 226,884 - Performance Rights |
18 Nov 2021 | Colin Goldschmidt | Issued | 248 | $9,882,724 | Issue of securities. |
18 Nov 2021 | Christopher Wilks | Issued | 15 | $596,965 | Issue of securities. 97,541 - Performance Rights |
18 Nov 2021 | Christopher Wilks | Issued | 94 | $3,766,113 | Issue of options. |
23 Sep 2021 | Colin Goldschmidt | Issued | 31 | $1,306,727 | Issue of securities. 187,475 - Performance Rights |
23 Sep 2021 | Christopher Wilks | Issued | 16 | $680,933 | Issue of securities. 82,523 - Performance Rights |
17 Sep 2021 | Christopher Wilks | Sell | 120 | $5,058,000 | On-market trade. |
16 Sep 2021 | Colin Goldschmidt | Sell | 200 | $8,436,480 | On-market trade. |
08 Sep 2021 | Colin Goldschmidt | Transfer | 164 | $6,870,338 | As advised by the company. 164,559 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt. |
08 Sep 2021 | Colin Goldschmidt | Transfer | 164 | $6,870,338 | As advised by the company. 164,559 shares were withdrawn from SHEST and legal title transferred to Dr Goldschmidt. |
08 Sep 2021 | Christopher Wilks | Transfer | 73 | $3,052,217 | As advised by the company. 73,107 shares were withdrawn from SHEST and legal title transferred to Mr Wilks. |
08 Sep 2021 | Christopher Wilks | Transfer | 73 | $3,052,217 | As advised by the company. 73,107 shares were withdrawn from SHEST and legal title transferred to Mr Wilks. |
07 Sep 2021 | Colin Goldschmidt | Buy | 164 | $3,557,765 | Exercise of options. |
07 Sep 2021 | Colin Goldschmidt | Exercise | 164 | $3,557,765 | Exercise of options. |
07 Sep 2021 | Christopher Wilks | Exercise | 73 | $1,580,573 | Exercise of options. |
07 Sep 2021 | Christopher Wilks | Issued | 73 | $1,580,573 | Exercise of options. |
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Mr Christopher David Wilks | Chief Financial OfficerFinance Director | Dec 1989 | Mr Wilks became Finance Director and Chief Financial Officer of Sonic Healthcare in 1993. He has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. Mr Wilks has held directorships in a number of public companies and is currently a Nonexecutive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996. |
Dr Colin Stephen Goldschmidt | Chief Executive OfficerManaging Director | Jan 1993 | Dr Goldschmidt is the CEO and Managing Director of Sonic Healthcare. He is a qualified medical doctor who then undertook specialist pathology training in Sydney, before gaining his qualification as a specialist pathologist in 1986. Dr Goldschmidt became CEO of Sonic in 1993 and has led Sonic's global expansion by committing the Company to a model of Medical Leadership, which incorporates operational and cultural attributes. He is a member of Sonic's Risk Management Committee and holds memberships with numerous industry, medical and laboratory associations. |
Mr Mark Raymond Compton | Non-Executive DirectorNon-Executive Chairman | Oct 2014 | Prof Compton has senior executive experience in healthcare services. His previous experience includes Chief Executive Officer of each of St Luke's Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. He was also Chief Executive Officer and Managing Director of the formerly ASX-listed companies SciGen Limited and Alpha Healthcare Limited. Prof. Compton has also held a number of non-executive director roles, including for formerly ASX-listed Independent Practitioner Network Limited, Chairman of the Woolcock Institute of Medical Research, nonexecutive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 45 years). In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017, and was appointed as a Member of the Order of Australia (AM) in January 2010. |
Dr Phillip James Dubois | Executive Director | Jul 2001 | Dr Dubois was appointed as an Executive Director of Sonic in July 2001 and retired from his executive position as CEO of Sonic's Imaging Division in June 2020. He remains on the Sonic Board as a Non-executive Director. Dr Dubois is a Non-executive Director of ASX-listed company EMVision Limited (since June 2021). A neuroradiologist and nuclear imaging specialist, he is currently an Associate Professor of Radiology at the University of Queensland Medical School. He has served on numerous government and craft group bodies, including the councils of the Royal Australian and New Zealand College of Radiologists and the Australian Medical Association, and as Vice-President of the Australian Diagnostic Imaging Association. He was a Nonexecutive Director of Magnetica Limited (from 2004 until March 2021). |
Mr Neville Mitchell | Non-Executive Director | Sep 2017 | Mr Mitchell was Chief Financial Officer and Company Secretary of ASX-listed Cochlear Limited (until March 2017), a medical device developer, manufacturer and seller of hearing devices. Mr Mitchell was a key Member of Cochlear's executive team, responsible for the setting and execution of the company's growth strategy from its listing in 1995 until his resignation. Mr Mitchell currently holds non-executive director roles with ASX-listed healthcare companies Fisher and Paykel Healthcare Corporation Limited (from November 2018) and Osprey Medical Inc. (from July 2012). He is a non-executive Director of QBiotics (from November 2017), an unlisted public company, and a Member of the Australian Board of Taxation. Mr Mitchell was previously a non-executive Director of ASX-listed Sirtex Medical Limited (from April 2017 to September 2018). He has also previously performed roles with a number of industry and government committees, including Chairman of the Group of 100 (Australia's peak body for senior finance executives), and Chairman, Standing Committee (Accounting and Auditing), for the Australian Securities and Investments Commission (ASIC). He is a member of the Risk Management committee. |
Mr Louis (Lou) James Panaccio | Non-Executive Director | Jun 2005 | Mr Panaccio is a Chartered Accountant with executive management experience in business and healthcare services. Mr Panaccio is currently on the boards of ASX-listed companies Avita Medical Limited (non-executive Chairman from July 2014) and Rhythm Biosciences Limited (non-executive Director from August 2017). He is also a non-executive Director of Unison Housing Limited, Invictus Biopharma Limited and NeuralDx Limited. Mr Panaccio was the Chief Executive Officer and executive Director of Melbourne Pathology (acquired by Sonic in 1999) for 10 years to 2001, the Chief Executive Officer of Monash IVF until 2009 and the executive Chairman of Health Networks Australia until 2017. He was also a non-executive Director of ASX-listed Genera Biosystems Limited from November 2010 until 28 June 2019 (Chairman from July 2011 until 28 June 2019). He is a member of the Risk Management committee. |
Dr Elizabeth Jane Wilson | Non-Executive Director | Jul 2010 | Dr Wilson is an independent non-executive Director with a background in finance, banking and medicine. She is a registered General Medical Practitioner. Dr Wilson is currently a Guardian of the Future Fund, non-executive Director of ASX-listed companies Transurban Group (since January 2017) and Costa Group Holdings Limited (from April 2019), and a non-executive Director of the General Sir John Monash Foundation. She is also Co-Chair of the Australian Government Advisory Board on Technology and Healthcare Competitiveness. Dr Wilson was Deputy Chancellor of the University of Queensland and has previously served on boards of ASX-listed companies, government-owned corporations and not-forprofit companies. She is Chair of the Risk Management Committee |
Professor Suzanne Crowe | Non-Executive Director | Apr 2020 | Professor Crowe has more than 30 years of experience as a clinical researcher. She was an integral part of Burnet's development as a HIV research organisation and held many leadership roles including Program Director, Healthy Ageing and Head of the Centre for Virology. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She was appointed as a Member of the Order of Australia (AM) in 2011 in recognition of her services to medical research in HIV/AIDS medicine and infectious diseases as an academic, clinician and researcher, and to professional associations. |
Ms Kathryn (Kate) Dianne Spargo | Non-Executive Director | Jul 2010 | Ms Spargo has gained business experience as both a legal advisor, having worked in private practice and government, and as a director. Ms Spargo has been a director of both listed and unlisted companies over the last 20 years and her current directorships include the ASX-listed companies CIMIC Group Limited (from September 2017), Adairs Limited (from May 2015) and Sigma Healthcare Limited (from December 2015). She is also a non-executive Director of CoInvest Limited, the Future Fuels Cooperative Research Centre, and Geelong Football Club Limited. Ms Spargo was previously a non-executive Director of Fletcher Building Limited (March 2012 to September 2017), UGL Limited (October 2010 to January 2017) and Xenith IP Group Limited (from April 2017 until 15 August 2019). |
Mr Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer | - | |
Paul Joseph Alexander | Company SecretaryDeputy Chief Financial Officer | - |
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
HSBC Custody Nominees (Australia) Limited | 176,333,314 | 36.10% |
J P Morgan Nominees Australia Pty Limited | 64,302,540 | 13.20% |
Citicorp Nominees Pty Limited | 35,477,522 | 7.41% |
Jardvan Pty Ltd | 15,109,474 | 3.15% |
National Nominees Limited | 12,629,188 | 2.64% |
BNP Paribas Noms Pty Ltd <Drp> | 7,110,445 | 1.48% |
BNP Paribas Nominees Pty Ltd <Agency Lending DRP A/C> | 7,027,569 | 1.47% |
Argo Investments Limited | 3,726,053 | 0.78% |
BNP Paribas Nominees Pty Ltd Six Sis Ltd <DRP A/C> | 3,596,510 | 0.75% |
Australian Foundation Investment Company Limited | 3,159,672 | 0.66% |
HSBC Custody Nominees (Australia) Limited <NT Comnwlth Super Corp A/C> | 2,711,736 | 0.57% |
Netwealth Investments Limited <Wrap Services A/C> | 2,202,828 | 0.46% |
Citicorp Nominees Pty Limited <Colonial First State INV A/C> | 2,187,813 | 0.46% |
Blaise Mentha | 2,000,000 | 0.42% |
Polly Pty Ltd <A/C Patterson Family> | 1,817,416 | 0.38% |
BNP Paribas Nominees Pty Ltd ACF Clearstream | 1,755,494 | 0.37% |
Bnp Paribas Nominees Pty Ltd HUB24 Custodial Serv Ltd <DRP A/C> | 1,727,193 | 0.36% |
Quintal Pty Ltd <Harken Family A/C> | 1,587,908 | 0.33% |
Australian Executor Trustees Limited <IPS Super A/C> | 1,557,059 | 0.33% |
Custodial Services Limited <Beneficiaries Holding A/C> | 1,213,818 | 0.25% |